Ken Fisher
CRNX icon

Ken Fisher’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ken Fisher’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.7M Buy
762,702
+4,043
+0.5% +$181K 0.01% 293
2025
Q4 		$35.3M Buy
758,659
+302
+0% +$13.4K 0.01% 263
2025
Q3 		$31.6M Buy
758,357
+21,273
+3% +$680K 0.01% 275
2025
Q2 		$21.2M Sell
737,084
-36,263
-5% -$1.12M 0.01% 311
2025
Q1 		$25.9M Buy
773,347
+214,060
+38% +$7.99M 0.01% 290
2024
Q4 		$28.6M Buy
559,287
+77,188
+16% +$4.32M 0.01% 295
2024
Q3 		$24.6M Buy
482,099
+37,429
+8% +$1.93M 0.01% 317
2024
Q2 		$19.9M Buy
444,670
+8,647
+2% +$399K 0.01% 338
2024
Q1 		$20.4M Sell
436,023
-5,272
-1% -$206K 0.01% 335
2023
Q4 		$15.7M Buy
441,295
+387,435
+719% +$11.9M 0.01% 360
2023
Q3 		$1.6M Sell
53,860
-14,411
-21% -$297K ﹤0.01% 666
2023
Q2 		$1.23M Hold
68,271
– – ﹤0.01% 735
2023
Q1 		$1.1M Sell
68,271
-8,653
-11% -$160K ﹤0.01% 765
2022
Q4 		$1.41M Buy
76,924
+23,568
+44% +$415K ﹤0.01% 710
2022
Q3 		$1.05M Buy
+53,356
New +$1.09M ﹤0.01% 658

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ken Fisher's CRNX Position: Q1 2026 in Review

Ken Fisher increased its Crinetics Pharmaceuticals (CRNX) stake by 0.53% in Q1 2026, buying an estimated $181K and bringing the position to 762,702 shares worth $27.7M. The position accounts for 0.01% of the portfolio, ranked #293.

Ken Fisher first reported a position in CRNX in Q3 2022 and has held it in 15 quarters since. The position peaked at $35.3M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Ken Fisher held 762,702 shares of Crinetics Pharmaceuticals worth $27.7M as of Q1 2026.
  • Ken Fisher bought 4,043 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $181K.
  • Crinetics Pharmaceuticals made up 0.01% of Ken Fisher's portfolio in Q1 2026, its #293 holding.
  • Ken Fisher first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Ken Fisher's Crinetics Pharmaceuticals position peaked at $35.3M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.